2229323
Project Grant
Overview
Grant Description
SBIR Phase I: Development of Arrays to Record Dynamic Interactions Between Single Cells - The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to enable experts in the biomedical field to improve understanding of how new therapeutic approaches are developed and perform in the context of a complex immune system.
This technology could enable new therapies to translate to patients faster, at less expense, and with higher rates of success. These therapeutics, such as antibodies, cell and gene therapies, and vaccines, can deliver excellent results when they work, but available therapies do not work for all patients.
To develop and deliver the next generation of therapies to improve the lives of patients, investigators need to be able to understand how immune cells and other cells move, interact, kill, and survive over time. This project allows researchers, developers, and manufacturing experts to understand the functional performance of new therapies earlier, more completely, and at lower expense.
Such single-cell analysis is a multi-billion market among commercial and non-profit markets. The proposed project will develop and rigorously validate a novel array consumable that enables scaling dynamic, single-cell analysis from an early access laboratory to any facility worldwide.
Initial design and testing activities for the next generation arrays using non-scalable proof of concept production methodologies have demonstrated the value of the dynamic single-cell functional analysis platform. This project will develop and evaluate two options for producing the arrays, one with an embossing technique and one with a three-dimensional printing technique.
Successful completion of this project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies faster, with higher rates of success, and at lower expense.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
This technology could enable new therapies to translate to patients faster, at less expense, and with higher rates of success. These therapeutics, such as antibodies, cell and gene therapies, and vaccines, can deliver excellent results when they work, but available therapies do not work for all patients.
To develop and deliver the next generation of therapies to improve the lives of patients, investigators need to be able to understand how immune cells and other cells move, interact, kill, and survive over time. This project allows researchers, developers, and manufacturing experts to understand the functional performance of new therapies earlier, more completely, and at lower expense.
Such single-cell analysis is a multi-billion market among commercial and non-profit markets. The proposed project will develop and rigorously validate a novel array consumable that enables scaling dynamic, single-cell analysis from an early access laboratory to any facility worldwide.
Initial design and testing activities for the next generation arrays using non-scalable proof of concept production methodologies have demonstrated the value of the dynamic single-cell functional analysis platform. This project will develop and evaluate two options for producing the arrays, one with an embossing technique and one with a three-dimensional printing technique.
Successful completion of this project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies faster, with higher rates of success, and at lower expense.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE I", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF22551
Grant Program (CFDA)
Awarding Agency
Place of Performance
Houston,
Texas
77204-0001
United States
Geographic Scope
Single Zip Code
Related Opportunity
22-551
Analysis Notes
Amendment Since initial award the End Date has been extended from 05/31/24 to 04/30/25.
Cehorus was awarded
Project Grant 2229323
worth $274,988
from in June 2023 with work to be completed primarily in Houston Texas United States.
The grant
has a duration of 1 year 10 months and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
SBIR Details
Research Type
SBIR Phase I
Title
SBIR Phase I: Development of arrays to record dynamic interactions between single cells
Abstract
The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase I project is to enable experts in the biomedical field to improve understanding of how new therapeutic approaches are developed and perform in the context of a complex immune system. This technology could enable new therapies to translate to patients faster, at less expense, and with higher rates of success. These therapeutics, such as antibodies, cell and gene therapies, and vaccines, can deliver excellent results when they work, but available therapies do not work for all patients. To develop and deliver the next generation of therapies to improve the lives of patients, investigators need to be able to understand how immune cells and other cells move, interact, kill, and survive over time. This project allows researchers, developers, and manufacturing experts to understand the functional performance of new therapies earlier, more completely, and at lower expense. Such single-cell analysis is a multi-billion market among commercial and non-profit markets._x000D_ _x000D_ The proposed project will develop and rigorously validate a novel array consumable that enables scaling dynamic, single-cell analysis from an early access laboratory to any facility worldwide. Initial design and testing activities for the next generation arrays using non-scalable proof of concept production methodologies have demonstrated the value of the dynamic single-cell functional analysis platform. This project will develop and evaluate two options for producing the arrays, one with an embossing technique and one with a three-dimensional printing technique. Successful completion of this project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies faster, with higher rates of success, and at lower expense._x000D_ _x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BT
Solicitation Number
NSF 22-551
Status
(Complete)
Last Modified 12/3/24
Period of Performance
6/1/23
Start Date
4/30/25
End Date
Funding Split
$275.0K
Federal Obligation
$0.0
Non-Federal Obligation
$275.0K
Total Obligated
Activity Timeline
Transaction History
Modifications to 2229323
Additional Detail
Award ID FAIN
2229323
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
LUF6ANBGK7F4
Awardee CAGE
8V6F5
Performance District
TX-18
Senators
John Cornyn
Ted Cruz
Ted Cruz
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Research and Related Activities, National Science Foundation (049-0100) | General science and basic research | Grants, subsidies, and contributions (41.0) | $274,988 | 100% |
Modified: 12/3/24